KR102410986B1 - Ｆｇｆ－１８ 화합물 투여 처방 - Google Patents

Ｆｇｆ－１８ 화합물 투여 처방 Download PDF

Info

Publication number
KR102410986B1
KR102410986B1 KR1020167025246A KR20167025246A KR102410986B1 KR 102410986 B1 KR102410986 B1 KR 102410986B1 KR 1020167025246 A KR1020167025246 A KR 1020167025246A KR 20167025246 A KR20167025246 A KR 20167025246A KR 102410986 B1 KR102410986 B1 KR 102410986B1
Authority
KR
South Korea
Prior art keywords
fgf
cartilage
compound
treatment
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167025246A
Other languages
English (en)
Korean (ko)
Other versions
KR20160116001A (ko
Inventor
크리스토프 하. 라델
한스 게링
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20160116001A publication Critical patent/KR20160116001A/ko
Application granted granted Critical
Publication of KR102410986B1 publication Critical patent/KR102410986B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020167025246A 2014-02-20 2015-02-20 Ｆｇｆ－１８ 화합물 투여 처방 Active KR102410986B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000600 2014-02-20
EP14000600.8 2014-02-20
PCT/EP2015/053631 WO2015124731A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (2)

Publication Number Publication Date
KR20160116001A KR20160116001A (ko) 2016-10-06
KR102410986B1 true KR102410986B1 (ko) 2022-06-17

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167025246A Active KR102410986B1 (ko) 2014-02-20 2015-02-20 Ｆｇｆ－１８ 화합물 투여 처방
KR1020167025245A Active KR102410988B1 (ko) 2014-02-20 2015-02-20 Ｆｇｆ－１８ 화합물 투여 처방

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167025245A Active KR102410988B1 (ko) 2014-02-20 2015-02-20 Ｆｇｆ－１８ 화합물 투여 처방

Country Status (25)

Country Link
US (2) US9724388B2 (enExample)
EP (2) EP3119417B1 (enExample)
JP (2) JP6431083B2 (enExample)
KR (2) KR102410986B1 (enExample)
CN (2) CN106232622A (enExample)
AR (2) AR099510A1 (enExample)
AU (2) AU2015220773B2 (enExample)
BR (2) BR112016018685A2 (enExample)
CA (1) CA2938791A1 (enExample)
DK (2) DK3107559T3 (enExample)
ES (2) ES2689071T3 (enExample)
HR (2) HRP20181570T1 (enExample)
HU (1) HUE040350T2 (enExample)
IL (2) IL247083B (enExample)
LT (2) LT3107559T (enExample)
MX (2) MX2016010871A (enExample)
NZ (1) NZ723148A (enExample)
PL (2) PL3107559T3 (enExample)
PT (2) PT3119417T (enExample)
RS (2) RS57709B1 (enExample)
RU (2) RU2700582C2 (enExample)
SG (2) SG11201606502YA (enExample)
SI (2) SI3107559T1 (enExample)
WO (2) WO2015124727A1 (enExample)
ZA (2) ZA201605548B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240147776A (ko) * 2023-03-29 2024-10-10 주식회사 아이프로테인테라퓨틱스 인터류킨-1 수용체 길항제 변이체 및 이의 용도

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181570T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18
ES2698117T3 (es) 2014-02-20 2019-01-31 Merck Patent Gmbh Implante que comprende FGF-18
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
LT3419625T (lt) 2016-02-22 2021-07-26 Novartis Ag Fxr agonistų panaudojimo būdai
LT3687558T (lt) 2017-09-29 2022-06-27 Merck Patent Gmbh Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
RS63292B1 (sr) * 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
JP7671249B2 (ja) * 2019-02-08 2025-05-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 変形性関節症が急速に進行するリスクがある患者の治療
CN122161846A (zh) * 2023-10-11 2026-06-05 四川至善唯新生物科技有限公司 治疗关节炎的组合物和方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009389A1 (en) 2004-07-06 2006-01-12 Moore Emma E Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1551426B1 (en) * 2002-10-07 2014-06-25 ZymoGenetics, Inc. Methods of administering fgf18
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
NZ574216A (en) * 2006-08-25 2011-11-25 Ares Trading Sa Treatment of cartilage disorders with fgf-18
US8207115B2 (en) * 2006-08-25 2012-06-26 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
AU2012232658B2 (en) * 2011-03-22 2016-06-09 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
HRP20181570T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18
KR102437057B1 (ko) 2014-02-20 2022-08-26 메르크 파텐트 게엠베하 이식편 이식 및 조직 공학 절차에 있어서의 ｆｇｆ－１８
ES2698117T3 (es) 2014-02-20 2019-01-31 Merck Patent Gmbh Implante que comprende FGF-18

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009389A1 (en) 2004-07-06 2006-01-12 Moore Emma E Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Jonathon Power et al., JOURNAL OF ORTHOPAEDIC RESEARCH, vol.32, no.5, pp.669-676(First published : 16 January 2014)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240147776A (ko) * 2023-03-29 2024-10-10 주식회사 아이프로테인테라퓨틱스 인터류킨-1 수용체 길항제 변이체 및 이의 용도
KR102920449B1 (ko) 2023-03-29 2026-02-03 주식회사 아이프로테인테라퓨틱스 인터류킨-1 수용체 길항제 변이체 및 이의 용도

Also Published As

Publication number Publication date
RU2016137292A (ru) 2018-03-21
ZA201605548B (en) 2018-12-19
PT3119417T (pt) 2018-10-31
JP2017512194A (ja) 2017-05-18
KR102410988B1 (ko) 2022-06-17
US9889179B2 (en) 2018-02-13
AU2015220777B2 (en) 2020-10-22
LT3119417T (lt) 2018-10-25
RS57709B1 (sr) 2018-12-31
EP3107559B1 (en) 2018-07-11
KR20160116000A (ko) 2016-10-06
JP6431083B2 (ja) 2018-11-28
JP6431082B2 (ja) 2018-11-28
CN106232622A (zh) 2016-12-14
SG11201606502YA (en) 2016-09-29
BR112016018696A2 (pt) 2017-10-17
MX2016010872A (es) 2016-11-17
RU2016137289A3 (enExample) 2018-10-19
US20170072017A1 (en) 2017-03-16
LT3107559T (lt) 2018-10-25
EP3119417B1 (en) 2018-07-11
AU2015220773B2 (en) 2020-10-08
HRP20181572T1 (hr) 2018-11-30
BR112016018685A2 (pt) 2017-10-17
PT3107559T (pt) 2018-10-31
JP2017507142A (ja) 2017-03-16
CN106456713A (zh) 2017-02-22
CA2938793A1 (en) 2015-08-27
IL247083A0 (en) 2016-09-29
KR20160116001A (ko) 2016-10-06
HUE040350T2 (hu) 2019-03-28
ES2689071T3 (es) 2018-11-08
RU2016137292A3 (enExample) 2018-09-17
WO2015124727A1 (en) 2015-08-27
NZ723139A (en) 2022-12-23
HRP20181570T1 (hr) 2018-11-30
AR099510A1 (es) 2016-07-27
ES2688551T3 (es) 2018-11-05
ZA201605547B (en) 2019-09-25
SG11201606505UA (en) 2016-09-29
SI3107559T1 (sl) 2018-11-30
DK3107559T3 (en) 2018-10-15
RU2691946C2 (ru) 2019-06-19
PL3107559T3 (pl) 2019-01-31
EP3119417A1 (en) 2017-01-25
AU2015220777A1 (en) 2016-09-01
IL247084A0 (en) 2016-09-29
NZ723148A (en) 2022-08-26
RU2700582C2 (ru) 2019-09-18
PL3119417T3 (pl) 2019-01-31
MX2016010871A (es) 2016-11-17
WO2015124731A1 (en) 2015-08-27
RU2016137289A (ru) 2018-03-21
US20170056474A1 (en) 2017-03-02
RS57853B1 (sr) 2018-12-31
US9724388B2 (en) 2017-08-08
AR099558A1 (es) 2016-08-03
SI3119417T1 (sl) 2018-11-30
CA2938791A1 (en) 2015-08-27
IL247084B (en) 2019-09-26
AU2015220773A1 (en) 2016-09-01
DK3119417T3 (en) 2018-10-22
IL247083B (en) 2019-09-26
EP3107559A1 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
KR102410988B1 (ko) Ｆｇｆ－１８ 화합물 투여 처방
KR101419961B1 (ko) Ｆｇｆ-18 로 연골 질환의 치료
CN101505787B (zh) 软骨障碍的治疗
RU2745453C2 (ru) Комбинированная композиция, содержащая соединение fgf-18
CA2938793C (en) Fgf-18 compound dosing regimen
HK1231754A1 (zh) Fgf-18化合物给药方案
HK1231895A1 (en) Fgf-18 compound dosing regimen
HK1129852B (en) Treatment of cartilage disorders
HK1129852A (en) Treatment of cartilage disorders

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5